280E Is Dead for Medical Cannabis: What Tax Relief Means for the Industry

The Tax Code That Nearly Killed an Industry

For more than a decade, Section 280E of the Internal Revenue Code has been the cannabis industry's most punishing obstacle—more damaging than banking restrictions, more costly than compliance burdens, and more demoralizing than the stigma that still clings to the plant. On April 22, 2026, that chapter began to close.

When the Department of Justice moved state-licensed medical marijuana from Schedule I to Schedule III, a cascade of tax consequences followed immediately. Because Section 280E only applies to businesses trafficking in Schedule I or II controlled substances, medical cannabis operators woke up on April 23 in a fundamentally different financial reality.

Understanding the 280E Nightmare

To appreciate what just changed, you need to understand how Section 280E worked in practice. The provision was originally enacted in 1982 after a convicted drug dealer successfully deducted business expenses related to his trafficking operation. Congress responded by adding a simple but devastating rule: businesses dealing in Schedule I or II substances cannot deduct ordinary business expenses from their federal taxes.

For legal cannabis businesses, this meant being taxed on gross income rather than net income. Every normal business expense that any other company takes for granted—rent, payroll, utilities, marketing, insurance, equipment—could not be deducted from taxable revenue.

The result was staggering. Effective tax rates for cannabis businesses routinely reached 60 to 80 percent, with some operators reporting rates exceeding 70 percent. A profitable dispensary earning $2 million in revenue with $1.5 million in operating expenses wouldn't be taxed on its $500,000 profit—it would be taxed on nearly the full $2 million.

This wasn't a theoretical problem. It drove companies into bankruptcy, deterred investment, and created a perverse incentive to remain in the illicit market where, at least, there were no federal tax obligations.

What Changed on April 22

The DOJ's Final Order reclassifying state-licensed medical cannabis to Schedule III effectively removes the statutory hook for 280E. As of April 22, 2026, medical cannabis businesses operating under qualifying state licenses are no longer trafficking in a Schedule I or II controlled substance—and therefore, 280E no longer bars them from claiming standard business deductions and credits.

The Treasury Department and IRS announced that tax guidance is forthcoming, and the implications are already being felt across the industry.

The Financial Impact: By the Numbers

For a typical mid-sized cannabis operation generating $5 million in annual revenue with $3.5 million in operating expenses, the difference is dramatic.

Under 280E, the company might have faced a federal tax bill approaching $1.5 million or more—taxes calculated on gross income minus only cost of goods sold, with no deductions for operating expenses.

Under normal Schedule III tax treatment, the same company would be taxed on its $1.5 million net profit, with a federal tax bill closer to $315,000 at the standard corporate rate. That's a savings of over $1 million annually for a single mid-sized operator.

Multiply that across the industry, and the aggregate tax savings could reach billions of dollars annually.

The Dual-License Complication

The tax relief isn't entirely straightforward for companies operating in both the medical and recreational markets. Because the April 22 order only moved medical cannabis to Schedule III—recreational marijuana remains Schedule I pending the June 29 hearing—multi-state operators with dual licenses face a split reality.

For these companies, 280E continues to apply to the recreational portion of their business. The IRS is expected to issue guidance on how businesses with multiple activities should apportion expenses between Schedule I recreational operations and Schedule III medical operations.

Legal experts anticipate this will create complex accounting challenges in the short term. Companies will need to carefully separate medical and recreational revenue streams, allocate shared expenses proportionally, and document their methodology to withstand potential IRS scrutiny.

What Smart Operators Are Doing Now

Forward-thinking cannabis companies are taking several immediate steps in response to the reclassification.

First, they're engaging tax advisors to evaluate whether amended returns for prior tax years may be appropriate. While the reclassification is effective as of April 22, 2026, some legal scholars argue that the ongoing rescheduling process creates potential claims for retroactive relief—though this remains a contested legal question.

Second, operators are restructuring their accounting systems to separate medical and recreational operations, preparing for the split-treatment environment that will likely persist until the June 29 hearing resolves the broader rescheduling question.

Third, companies are reassessing their capital expenditure plans. With dramatically improved cash flow from tax relief, investments that were previously unaffordable—facility upgrades, technology adoption, market expansion—suddenly become viable.

Impact on M&A and Valuations

The 280E relief is already reshaping cannabis M&A activity and company valuations. Analysts note that companies with strong medical-license portfolios have seen immediate valuation boosts, as their projected cash flows improve dramatically under normal tax treatment.

Cannabis stocks surged following the announcement, with major operators seeing gains of 13 to 20 percent. The AdvisorShares Pure Cannabis ETF jumped approximately 20 percent, reflecting market confidence that the tax relief will translate to improved bottom lines.

For potential acquirers—both within and outside the cannabis industry—the elimination of 280E makes cannabis businesses look far more attractive as investment targets. Expected deal flow in the second half of 2026 is projected to accelerate significantly.

The Path Forward

The ultimate resolution of the 280E question depends on the June 29 DEA hearing. If all marijuana moves to Schedule III, the tax relief extends to the entire legal cannabis industry, eliminating the dual-license complications and creating a level playing field with other Schedule III businesses.

Until then, the cannabis industry is operating in a transitional environment—better than before, but not yet at its destination. For medical cannabis operators, April 22 marked the beginning of a new era. For the broader industry, the finish line is visible but not yet crossed.

What's already clear is that the financial foundation of the cannabis industry has shifted permanently. The days of 70 percent effective tax rates are over for medical cannabis, and likely numbered for the industry as a whole. That changes everything.

For shoppers tracking how rescheduling reaches the storefront, Budpedia's cannabis dispensary directory covers 7,400+ verified medical and recreational retailers across every legal state, with current menus and pricing as 280E relief works its way through operator margins.